Novel approaches for the treatment of ventricular tachycardia

Ventricular tachycardia(VT) is a crucial cause of sudden cardiac death(SCD) and a primary cause of mortality and morbidity in patients with structural cardiac disease. VT includes clinical disorders varying from benign to lifethreatening. Most life-threatening episodes are correlated with coronary artery disease, but the risk of SCD varies in certain populations, with various underlying heart conditions, specific family history, and genetic variants. The targets of VT management are symptom alleviation, improved quality of life, reduced implantable cardioverter defibrillator shocks, prevention of reduction of left ventricular function, reduced risk of SCD, and improved overall survival. Antiarrhythmic drug therapy and endocardial catheter ablation remains the cornerstone of guideline-endorsed VT treatment strategies in patients with structural cardiac abnormalities. Novel strategies such as epicardial ablation, surgical cryoablation, transcoronary alcohol ablation, pre-procedural imaging, and stereotactic ablative radiotherapy are an appealing area of res-earch. In this review, we gathered all recent advances in innovative therapies as well as experimental evidence focusing on different aspects of VT treatment that could be significant for future favorable clinical applications.

Conduction abnormalities after transcatheter aortic valve implantation

在最后几年里， transcatheter 大动脉的阀门培植(TAVI ) 为外科的大动脉的代替与严重大动脉的狭窄和高风险在病人成为了一个其他的过程。由于在大动脉的阀门结构和心的传导系统之间的解剖关联，在 TAVI 以后的最普通的复杂并发症之一是哪个的传导系统骚乱包括为永久心律调整器培植的捆分支块，完全的心块和需要。尽管这些骚乱通常不是致命的，他们可以在病人状态和长术语幸存上有大影响。为传导骚乱的几个风险因素被识别了，先存在它包括年龄，心的解剖， periprocedural 因素，植入的阀门的类型畸形和 comorbidities。当这种技术对医生变得更熟悉，病人们应该小心地为传导畸形的发展为风险因素被屏蔽在 TAVI 以后以便提供有效预防和合适的治疗。